How many insider trades does FilingIQ track for HOWL?

FilingIQ tracks 183 Form 4 insider transactions for HOWL (Werewolf Therapeutics, Inc.), covering filings from May 4, 2021 onwards. 19 of those were filed in the last 90 days.

Are HOWL insiders net buyers or net sellers?

Across the full Form 4 history for HOWL, 19 transactions (10%) were open-market purchases and 135 (74%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does HOWL insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is HOWL in?

Werewolf Therapeutics, Inc. (HOWL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $37.87M.

HOWL insider trading

NasdaqGS Healthcare

Werewolf Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

183

Last 90 days

Buys / sells

10% / 74%

Market cap

$37.87M

About Werewolf Therapeutics, Inc.

Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.

Company website: werewolftx.com

HOWL insider activity at a glance

FilingIQ has scored 183 insider transactions for HOWL since May 4, 2021. The most recent filing in our index is dated May 13, 2026.

Across the full history, 19 open-market purchases and 135 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on HOWL insider trades is 49.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live HOWL trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Top insiders trading HOWL

GADICKE ANSBERT

35 trades · score 74.0

Frequently asked

How many insider trades does FilingIQ track for HOWL?: FilingIQ tracks 183 Form 4 insider transactions for HOWL (Werewolf Therapeutics, Inc.), covering filings from May 4, 2021 onwards. 19 of those were filed in the last 90 days.
Are HOWL insiders net buyers or net sellers?: Across the full Form 4 history for HOWL, 19 transactions (10%) were open-market purchases and 135 (74%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does HOWL insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is HOWL in?: Werewolf Therapeutics, Inc. (HOWL) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $37.87M.

Methodology & sources

Every HOWL insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.